Microangiopathic	microangiopathic	O	O	OTHERS	I
hemolytic	hemolytic	O	DISEASE	OTHERS	I
anemia	anemia	O	DISEASE	OTHERS	I
complicating	complicating	O	O	O	O
FK506	fk506	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
tacrolimus	tacrolimus	CHEMICALS	O	OTHERS	I
)	)	O	O	O	O
therapy	therapy	O	O	O	O
.	.	O	O	O	O

We	we	O	O	O	O
describe	describe	O	O	O	O
3	3	O	O	O	O
episodes	episodes	O	O	O	O
of	of	O	O	O	O
microangiopathic	microangiopathic	O	O	OTHERS	I
hemolytic	hemolytic	O	DISEASE	OTHERS	I
anemia	anemia	O	DISEASE	OTHERS	I
(	(	O	O	O	O
MAHA	maha	O	DISEASE	OTHERS	I
)	)	O	O	O	O
in	in	O	O	O	O
2	2	O	O	O	O
solid	solid	O	O	O	O
organ	organ	O	O	O	O
recipients	recipients	O	O	O	O
under	under	O	O	O	O
FK506	fk506	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
tacrolimus	tacrolimus	CHEMICALS	O	OTHERS	I
)	)	O	O	O	O
therapy	therapy	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
both	both	O	O	O	O
cases	cases	O	O	O	O
,	,	O	O	O	O
discontinuation	discontinuation	O	O	O	O
of	of	O	O	O	O
FK506	fk506	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
treatment	treatment	O	O	O	O
with	with	O	O	O	O
plasma	plasma	O	O	O	O
exchange	exchange	O	O	O	O
,	,	O	O	O	O
fresh	fresh	O	O	O	O
frozen	frozen	O	O	O	O
plasma	plasma	O	O	O	O
replacement	replacement	O	O	O	O
,	,	O	O	O	O
corticosteroids	corticosteroids	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
aspirin	aspirin	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
dipyridamole	dipyridamole	CHEMICALS	O	OTHERS	I
led	led	O	O	O	O
to	to	O	O	O	O
resolution	resolution	O	O	O	O
of	of	O	O	O	O
MAHA	maha	O	DISEASE	OTHERS	I
.	.	O	O	O	O

In	in	O	O	O	O
one	one	O	O	O	O
patient	patient	O	O	O	O
,	,	O	O	O	O
reintroduction	reintroduction	O	O	O	O
of	of	O	O	O	O
FK506	fk506	CHEMICALS	O	OTHERS	I
led	led	O	O	O	O
to	to	O	O	O	O
rapid	rapid	O	O	O	O
recurrence	recurrence	O	O	O	O
of	of	O	O	O	O
MAHA	maha	O	DISEASE	OTHERS	I
.	.	O	O	O	O

FK506-associated	fk506-associated	O	O	O	O
MAHA	maha	O	DISEASE	OTHERS	I
is	is	O	O	O	O
probably	probably	O	O	O	O
rare	rare	O	O	O	O
but	but	O	O	O	O
physicians	physicians	O	O	O	O
must	must	O	O	O	O
be	be	O	O	O	O
aware	aware	O	O	O	O
of	of	O	O	O	O
this	this	O	O	O	O
severe	severe	O	O	O	O
complication	complication	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
our	our	O	O	O	O
experience	experience	O	O	O	O
and	and	O	O	O	O
according	according	O	O	O	O
to	to	O	O	O	O
the	the	O	O	O	O
literature	literature	O	O	O	O
,	,	O	O	O	O
FK506	fk506	CHEMICALS	O	OTHERS	I
does	does	O	O	O	O
not	not	O	O	O	O
seem	seem	O	O	O	O
to	to	O	O	O	O
cross-react	cross-react	O	O	O	O
with	with	O	O	O	O
cyclosporin	cyclosporin	CHEMICALS	O	OTHERS	I
A	a	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
CyA	cya	O	O	OTHERS	I
)	)	O	O	O	O
,	,	O	O	O	O
an	an	O	O	O	O
immuno-suppressive	immuno-suppressive	O	O	O	O
drug	drug	O	O	O	O
already	already	O	O	O	O
known	known	O	O	O	O
to	to	O	O	O	O
induce	induce	O	O	O	O
MAHA	maha	O	DISEASE	OTHERS	I
.	.	O	O	O	O

